Human Leucocyte Antigen Class I-redirected Anti-tumour CD4 T Cells Require a Higher T Cell Receptor Binding Affinity for Optimal Activity Than CD8 T Cells

Overview

Journal Clin Exp Immunol

Publisher Oxford University Press

Specialty Allergy & Immunology

Date 2016 Jun 22

PMID 27324616

Citations 22

Authors

M P Tan

G M Dolton

A B Gerry

J E Brewer

A D Bennett

N J Pumphrey

B K Jakobsen

A K Sewell

Affiliations

Soon will be listed here.

Abstract

CD4 T helper cells are a valuable component of the immune response towards cancer. Unfortunately, natural tumour-specific CD4 T cells occur in low frequency, express relatively low-affinity T cell receptors (TCRs) and show poor reactivity towards cognate antigen. In addition, the lack of human leucocyte antigen (HLA) class II expression on most cancers dictates that these cells are often unable to respond to tumour cells directly. These deficiencies can be overcome by transducing primary CD4 T cells with tumour-specific HLA class I-restricted TCRs prior to adoptive transfer. The lack of help from the co-receptor CD8 glycoprotein in CD4 cells might result in these cells requiring a different optimal TCR binding affinity. Here we compared primary CD4 and CD8 T cells expressing wild-type and a range of affinity-enhanced TCRs specific for the HLA A*0201-restricted NY-ESO-1- and gp100 tumour antigens. Our major findings are: (i) redirected primary CD4 T cells expressing TCRs of sufficiently high affinity exhibit a wide range of effector functions, including cytotoxicity, in response to cognate peptide; and (ii) optimal TCR binding affinity is higher in CD4 T cells than CD8 T cells. These results indicate that the CD4 T cell component of current adoptive therapies using TCRs optimized for CD8 T cells is below par and that there is room for substantial improvement.

Citing Articles

Dolton G, Thomas H, Tan L, Rius Rafael C, Doetsch S, Ionescu G J Clin Invest. 2025; 135(1).

PMID: 39744940 PMC: 11684821. DOI: 10.1172/JCI181895.

NY-ESO-1 antigen: A promising frontier in cancer immunotherapy.

Alsalloum A, Shevchenko J, Sennikov S Clin Transl Med. 2024; 14(9):e70020.

PMID: 39275923 PMC: 11399778. DOI: 10.1002/ctm2.70020.

Strategies and rules for tuning TCR-derived therapy.

Mo G, Lu X, Wu S, Zhu W Expert Rev Mol Med. 2023; 26:e4.

PMID: 38095091 PMC: 11062142. DOI: 10.1017/erm.2023.27.

Identification of cross-reactive CD8 T cell receptors with high functional avidity to a SARS-CoV-2 immunodominant epitope and its natural mutant variants.

Hu C, Shen M, Han X, Chen Q, Li L, Chen S Genes Dis. 2021; 9(1):216-229.

PMID: 34222571 PMC: 8240504. DOI: 10.1016/j.gendis.2021.05.006.

Optogenetic Tuning of Ligand Binding to The Human T cell Receptor Using The opto-ligand-TCR System.

Yousefi O, Horner M, Wess M, Idstein V, Weber W, Schamel W Bio Protoc. 2021; 10(5):e3540.

PMID: 33659514 PMC: 7842703. DOI: 10.21769/BioProtoc.3540.

References

Schmid D, Irving M, Posevitz V, Hebeisen M, Posevitz-Fejfar A, Sarria J . Evidence for a TCR affinity threshold delimiting maximal CD8 T cell function. J Immunol. 2010; 184(9):4936-46. DOI: 10.4049/jimmunol.1000173. View

Robbins P, Li Y, El-Gamil M, Zhao Y, Wargo J, Zheng Z . Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions. J Immunol. 2008; 180(9):6116-31. PMC: 2424230. DOI: 10.4049/jimmunol.180.9.6116. View

Yang I, Kremen T, Giovannone A, Paik E, Odesa S, Prins R . Modulation of major histocompatibility complex Class I molecules and major histocompatibility complex-bound immunogenic peptides induced by interferon-alpha and interferon-gamma treatment of human glioblastoma multiforme. J Neurosurg. 2004; 100(2):310-9. DOI: 10.3171/jns.2004.100.2.0310. View

Storkus W, Howell D, Salter R, Dawson J, Cresswell P . NK susceptibility varies inversely with target cell class I HLA antigen expression. J Immunol. 1987; 138(6):1657-9. View

Chhabra A, Yang L, Wang P, Comin-Anduix B, Das R, Chakraborty N . CD4+CD25- T cells transduced to express MHC class I-restricted epitope-specific TCR synthesize Th1 cytokines and exhibit MHC class I-restricted cytolytic effector function in a human melanoma model. J Immunol. 2008; 181(2):1063-70. PMC: 2715965. DOI: 10.4049/jimmunol.181.2.1063. View

Chervin A, Stone J, Soto C, Engels B, Schreiber H, Roy E . Design of T-cell receptor libraries with diverse binding properties to examine adoptive T-cell responses. Gene Ther. 2012; 20(6):634-44. PMC: 5330764. DOI: 10.1038/gt.2012.80. View

Rapoport A, Stadtmauer E, Binder-Scholl G, Goloubeva O, Vogl D, Lacey S . NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat Med. 2015; 21(8):914-921. PMC: 4529359. DOI: 10.1038/nm.3910. View

Wooldridge L, van den Berg H, Glick M, Gostick E, Laugel B, Hutchinson S . Interaction between the CD8 coreceptor and major histocompatibility complex class I stabilizes T cell receptor-antigen complexes at the cell surface. J Biol Chem. 2005; 280(30):27491-501. PMC: 2441837. DOI: 10.1074/jbc.M500555200. View

Miles K, Miles J, Madura F, Sewell A, Cole D . Real time detection of peptide-MHC dissociation reveals that improvement of primary MHC-binding residues can have a minimal, or no, effect on stability. Mol Immunol. 2010; 48(4):728-32. PMC: 3032881. DOI: 10.1016/j.molimm.2010.11.004. View

10.

Ray S, Chhabra A, Chakraborty N, Hegde U, Dorsky D, Chodon T . MHC-I-restricted melanoma antigen specific TCR-engineered human CD4+ T cells exhibit multifunctional effector and helper responses, in vitro. Clin Immunol. 2010; 136(3):338-47. PMC: 2917536. DOI: 10.1016/j.clim.2010.04.013. View

11.

Matsuzaki J, Tsuji T, Luescher I, Shiku H, Mineno J, Okamoto S . Direct tumor recognition by a human CD4(+) T-cell subset potently mediates tumor growth inhibition and orchestrates anti-tumor immune responses. Sci Rep. 2015; 5:14896. PMC: 4597193. DOI: 10.1038/srep14896. View

12.

Xue S, Gao L, Ahmadi M, Ghorashian S, Barros R, Pospori C . Human MHC Class I-restricted high avidity CD4 T cells generated by co-transfer of TCR and CD8 mediate efficient tumor rejection in vivo. Oncoimmunology. 2013; 2(1):e22590. PMC: 3583927. DOI: 10.4161/onci.22590. View

13.

Odunsi K, Qian F, Matsuzaki J, Mhawech-Fauceglia P, Andrews C, Hoffman E . Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proc Natl Acad Sci U S A. 2007; 104(31):12837-42. PMC: 1937553. DOI: 10.1073/pnas.0703342104. View

14.

Aleksic M, Liddy N, Molloy P, Pumphrey N, Vuidepot A, Chang K . Different affinity windows for virus and cancer-specific T-cell receptors: implications for therapeutic strategies. Eur J Immunol. 2012; 42(12):3174-9. PMC: 3776049. DOI: 10.1002/eji.201242606. View

15.

Lissina A, Ladell K, Skowera A, Clement M, Edwards E, Seggewiss R . Protein kinase inhibitors substantially improve the physical detection of T-cells with peptide-MHC tetramers. J Immunol Methods. 2008; 340(1):11-24. PMC: 3052435. DOI: 10.1016/j.jim.2008.09.014. View

16.

Tan M, Gerry A, Brewer J, Melchiori L, Bridgeman J, Bennett A . T cell receptor binding affinity governs the functional profile of cancer-specific CD8+ T cells. Clin Exp Immunol. 2014; 180(2):255-70. PMC: 4408161. DOI: 10.1111/cei.12570. View

17.

Schroder K, Hertzog P, Ravasi T, Hume D . Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol. 2003; 75(2):163-89. DOI: 10.1189/jlb.0603252. View

18.

Kershaw M, Westwood J, Darcy P . Gene-engineered T cells for cancer therapy. Nat Rev Cancer. 2013; 13(8):525-41. DOI: 10.1038/nrc3565. View

19.

Cole D, Pumphrey N, Boulter J, Sami M, Bell J, Gostick E . Human TCR-binding affinity is governed by MHC class restriction. J Immunol. 2007; 178(9):5727-34. DOI: 10.4049/jimmunol.178.9.5727. View

20.

Robbins P, Morgan R, Feldman S, Yang J, Sherry R, Dudley M . Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011; 29(7):917-24. PMC: 3068063. DOI: 10.1200/JCO.2010.32.2537. View